Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

A number of other research firms have also weighed in on APTO. Canaccord Genuity Group cut their price objective on shares of Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, May 16th. Piper Sandler reissued an “overweight” rating and issued a $5.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, June 14th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $14.83.

Aptose Biosciences Trading Down 2.8 %

Shares of APTO opened at $0.71 on Monday. The stock has a market cap of $12.86 million, a P/E ratio of -0.11 and a beta of 1.26. The company has a 50-day moving average of $0.99 and a two-hundred day moving average of $1.53. Aptose Biosciences has a 12-month low of $0.70 and a 12-month high of $5.10.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.09. As a group, analysts forecast that Aptose Biosciences will post -2.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned 0.16% of Aptose Biosciences as of its most recent SEC filing. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.